多机构研究发现抗肾病蛋白抗体可能参与移植后局灶节段性肾小球硬化复发
复发性FSGS患者移植前或复发期间血浆抗肾病蛋白抗体水平显著升高,中位899 U/mL( cutoff 231 U/mL),复发时移植物活检显示IgG点状沉积与肾病蛋白共定位,且肾病蛋白酪氨酸磷酸化增加;缓解后抗体水平下降至155 U/mL,活检IgG信号消失。遗传性FSGS及无复发的非遗传性FSGS患者抗体水平与30例对照相当。
要点
- 移植后复发FSGS患者抗肾病蛋白抗体水平显著升高,中位899 U/mL。
- 复发时活检见IgG与肾病蛋白共定位,伴肾病蛋白磷酸化增加。
- 缓解后抗体水平下降,活检IgG信号消失,提示抗体参与复发。
核心结论
- 循环抗肾病蛋白抗体可能是移植后复发性FSGS的致病 circulating factor,可能通过肾病蛋白磷酸化介导。
研究设计与样本
- 多机构研究纳入22例日本儿童肾移植受者,包括8例遗传性FSGS和14例非遗传性(推测原发性)FSGS。
主要发现
- 复发时移植物活检显示IgG点状沉积与肾病蛋白共定位,肾病蛋白定位改变伴酪氨酸磷酸化及Src homology and collagen homology A表达增加。
- 5例缓解后样本抗体水平降至155(53,367)U/mL,缓解后活检IgG信号消失且肾病蛋白表达模式正常。
- 遗传性FSGS及无复发的非遗传性FSGS患者抗体水平与30例对照相当,活检无IgG信号且肾病蛋白表达正常。
关键数值与推荐
- 抗肾病蛋白抗体ELISA检测 cut off 值为231 U/mL。
- 复发性FSGS患者移植前或复发期间抗体中位899(831,1292)U/mL。
- 缓解后5例患者抗体中位155(53,367)U/mL。
临床怎么用
- 对于移植后复发FSGS的儿童受者,可考虑检测血浆抗肾病蛋白抗体辅助诊断。
- 复发时移植物活检可关注IgG与肾病蛋白共定位及肾病蛋白磷酸化改变。
- 抗体水平动态监测可能有助于评估复发缓解状态。
局限性
- 样本量小(22例),仅纳入日本儿童受者,需更大规模及多种族研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Possible roles of anti-nephrin antibodies in post-transplant recurrent focal segmental glomerulosclerosis (FSGS) have been reported recently. To confirm these preliminary results, we performed a multi-institutional study of 22 Japanese pediatric kidney transplant recipients with FSGS including eight genetic FSGS and 14 non-genetic (presumed primary) FSGS. Eleven of the 14 non-genetic FSGS patients had post-transplant recurrent FSGS. Median (interquartile range) plasma levels of anti-nephrin antibodies in post-transplant recurrent FSGS measured using ELISA were markedly high at 899 (831, 1292) U/mL (cutoff 231 U/mL) before transplantation or during recurrence. Graft biopsies during recurrence showed punctate IgG deposition co-localized with nephrin that had altered localization with increased nephrin tyrosine phosphorylation and Src homology and collagen homology A expressions. Graft biopsies after remission showed no signals for IgG and a normal expression pattern of nephrin. Anti-nephrin antibody levels decreased to 155 (53, 367) U/mL in five patients with samples available after remission. In patients with genetic FSGS as in those with non-genetic FSGS without recurrence, anti-nephrin antibody levels were comparable to those of 30 control individuals, and graft biopsies had no signals for IgG and a normal expression pattern of nephrin. Thus, our results suggest that circulating anti-nephrin antibodies are a possible candidate for circulating factors involved in the pathogenesis of post-transplant recurrent FSGS and that this may be mediated by nephrin phosphorylation. Larger studies including other ethnicities are required to confirm this finding.
引用
- Shirai Y, Miura K, Ishizuka K, et al. A multi-institutional study found a possible role of anti-nephrin antibodies in post-transplant focal segmental glomerulosclerosis recurrence. Kidney Int. 2023. PMID: 38110152. doi:10.1016/j.kint.2023.11.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。